American society of clinical oncology policy statement on medicaid reform

Journal of Clinical Oncology

Volumn 32, Issue 36, 2014, Pages 4162-4167

  Polite, Blase N ^a   Griggs, Jennifer J ^b   Moy, Beverly ^b   Lathan, Christopher ^c   DuPont, Nefertiti C ^b   Villani, Gina ^b   Wong, Sandra L ^b   Halpern, Michael T ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; DRUG COST; GENETIC SCREENING; HEALTH INSURANCE; HOME CARE; LAW; MEDICAID; MEDICAL SOCIETY; ONCOLOGY; POLICY; POVERTY; PRACTICE GUIDELINE; REIMBURSEMENT; CLINICAL TRIAL (TOPIC); COST; EARLY DIAGNOSIS; ECONOMICS; HEALTH CARE POLICY; HUMAN; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; EARLY DETECTION OF CANCER; GENETIC TESTING; HEALTH CARE REFORM; HEALTH POLICY; HUMANS; MEDICAID; MEDICAL ONCOLOGY; UNITED STATES;

EID: 84919752983     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3452     Document Type: Article

References (50)

1. Sommers BD, Swartz K, Epstein A: Policy makers should prepare for major uncertainties in Medicaid enrollment, costs, and needs for physicians under health reform. Health Aff (Millwood) 30:2186-2193, 2011
2. The Henry J. Kaiser Family Foundation, Kaiser commission on Medicaid and the Uninsured: Expanding Medicaid Under Health Reform: A Look at Adults at or Below 133% of Poverty. http://kff.org/health-reform/issue-brief/expanding-medicaid-under-health-reform-alook/
3. Herz EJ: Traditional Versus Benchmark Benefits Under Medicaid: Congressional Research Service Report R42478. http://www.law.umaryland.edu/marshall/crsreports/crsdocuments/R42478-04232013.pdf
4. Sommers BD, Baicker K, Epstein AM: Mortality and access to care among adults after state Medicaid expansions. N Engl J Med 367:1025-1034, 2012
5. Chien LN, Adams EK, Yang Z: Medicaid enrollment at early stage of disease: The Breast and Cervical Cancer Prevention and Treatment Act in Georgia. Inquiry 48:197-208, 2011
6. Bradley CJ, Gardiner J, Given CW, et al: Cancer, Medicaid enrollment, and survival disparities. Cancer 103:1712-1718, 2005
7. Subramanian S, Trogdon J, Ekwueme DU, et al: Cost of breast cancer treatment in Medicaid: Implications for state programs providing coverage for low-income women. Med Care 49:89-95, 2011
8. Griggs JJ, Hawley ST, Graff JJ: Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30:3058-3064, 2012
9. Groth SS, Al-Refaie WB, Zhong W, et al: Effect of insurance status on the surgical treatment of early-stage non-small cell lung cancer. Ann Thorac Surg 95:1221-1226, 2013
10. Halpern MT, Ward EM, Pavluck AL, et al: Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: A retrospective analysis. Lancet Oncol 9:222-231, 2008
11. Kelz RR, Gimotty PA, Polsky D, et al: Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer 101:2187-2194, 2004
12. Koroukian SM, Bakaki PM, Raghavan D: Survival disparities by Medicaid status: An analysis of 8 cancers. Cancer 118:4271-4279, 2012
13. Mosunjac M, Park J, Strauss A, et al: Time to treatment for patients receiving BCS in a public and a private university hospital in Atlanta. Breast J 18:163-167, 2012
14. Slatore CG, Au DH, Gould MK: An official American Thoracic Society systematic review: Insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med 182:1195-1205, 2010
15. Trinh QD, Schmitges J, Sun M, et al: Morbidity and mortality of radical prostatectomy differs by insurance status. Cancer 118:1803-1810, 2012
16. Voti L, Richardson LC, Reis I, et al: The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. Breast Cancer Res Treat 95:89-95, 2006
17. Ward E, Halpern M, Schrag N, et al: Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 58:9-31, 2008
18. Farkas DT, Greenbaum A, Singhal V, et al: Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital. Am J Manag Care 18:SP65-SP70, 2012
19. Dasenbrock HH, Wolinsky JP, Sciubba DM: The impact of insurance status on outcomes after surgery for spinal metastases. Cancer 118:4833-4841, 2012
20. Penson DF, Stoddard ML, Pasta DJ, et al: The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol 54:350-358, 2001
21. Wu X, Chen VW, Andrews PA, et al: Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. J La State Med Soc 156:255-261, 2004
22. Chen F, Puig M, Yermilov I, et al: Using breast cancer quality indicators in a vulnerable population. Cancer 117:3311-3321, 2011
23. Slatore CG, Au DH, Gould MK: An official American Thoracic Society systematic review: Insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med 182:1195-1205, 2010
24. Woods LM, Rachet B, Coleman MP: Origins of socio-economic inequalities in cancer survival: A review. Ann Oncol 17:5-19, 2006
25. Bradley CJ, Dahman B, Shickle LM, et al: Surgery wait times and specialty services for insured and uninsured breast cancer patients: Does hospital safety net status matter? Health Serv Res 47:677-697, 2012
26. Cunningham PJ, Hadley J: Effects of changes in incomes and practice circumstances on physicians' decisions to treat charity and Medicaid patients. Milbank Q 86:91-123, 2008
27. Shen YC, Zuckerman S: The effect of Medicaid payment generosity on access and use among beneficiaries. Health Serv Res 40:723-744, 2005
28. Gray B: Do Medicaid physician fees for prenatal services affect birth outcomes? J Health Econ 20:571-590, 2001
29. Halpern MT, Romaire MA, Haber SG, et al: Impact of state-specific Medicaid policies on timely receipt of breast cancer surgery. J Clin Oncol 32: 410s, 2014 (suppl; abstr 6500)
30. Henry J. Kaiser Family Foundation: Status of State Action on the Medicaid Expansion Decision. http:// kff.org/medicaid/state-indicator/state-activity-aroundexpanding-medicaid-under-the-affordable-care-act/
31. Chirikos TN, Ruckdeschel JC, Krischer JP: Impact of clinical trials on the cost of cancer care. Med Care 39:373-383, 2001
32. Fireman BH, Fehrenbacher L, Gruskin EP, et al: Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 92:136-142, 2000
33. Goldman DP, Berry SH, McCabe, MS, et al: Incremental treatment costs in National Cancer Institute-sponsored clinical trials. JAMA 289:2970-2977, 2003
34. Wagner JL, Alberts SR, Sloan JA, et al: Incremental costs of enrolling cancer patients in clinical trials: A population-based study. J Natl Cancer Inst 91:847-853, 1999
35. Gross CP, Murthy V, Li Y, et al: Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 96:1063-1069, 2004
36. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004:2720-2726, 2004
37. The Henry J. Kaiser Family Foundation, Kaiser Commission on Medicaid and the Uninsured: Coverage of Preventive Services for Adults in Medicaid. http://kff.org/health-reform/issue-brief/coverage-of-preventiveservices-for-adults-in/
38. Centers for Medicare and Medicaid Services: Affordable Care Act Implementation FAQs: Set 12. http://www.cms.gov/CCIIO/Resources/Fact-Sheetsand-FAQs/aca-implementation-faqs12.html
39. Yang KY, Caughey, AB, Little, SE et al: A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 10:535-543, 2011
40. Anderson K, Jacobson JS, Heltjan DF, et al: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144:397-406, 2006
41. Grann VR, Panageas KS, Whang W, et al: Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16:979-998, 1998
42. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997
43. Schmeler KM, Lynch HT, Chen L, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269, 2006
44. Lindor NM, Petersen GM, Hadley DW, et al: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 296:1507-1517, 2006
45. Bonadona V, Bonaïti B, Olschwang S, et al: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304-2310, 2011
46. Sabatino SA, Thompson MD, Richardson LC et al: Health insurance and other factors associated with mammography surveillance among breast cancer survivors: Results from a national survey. Med Care 50:270-276, 2012
47. American Society of Clinical Oncology: A policy statement on the 340B Drug Pricing Program. J Oncol Pract [epub ahead of print on April 15, 2014]
48. The Henry J. Kaiser Family Foundation: Medicaidto- Medicare fee index. http://kff.org/medicaid/stateindicator/medicaid-to-medicare-fee-index/
49. Decker SL: In 2011 nearly one-third of physicians said they would not accept new Medicaid patients, but rising fees may help. Health Aff (Millwood) 31:1673-1679, 2012
50. Institute of Medicine: Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC, National Academies Press, 2013